Soleno Therapeutics Inc. (SLNO): Analysts See Major Upside [Yahoo! Finance]
Soleno Therapeutics, Inc. (SLNO)
Last soleno therapeutics, inc. earnings: 5/13 08:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.soleno.life/investor-overview
Company Research
Source: Yahoo! Finance
an Overweight rating on the stock and set a $123 price target. The positive stance is in response to the company reaching 12.5% market share in its Prader-Willi Syndrome (PWS) treatment, Vykat. Consequently, the company is expected to generate $98.67 million in revenue even as the discontinuation rate on the flagship drug remains at 15%. Cantor Fitzgerald expects Soleno to add 1,000 patients every 9 to 12 months, representing 10% of the total addressable market. While the company has enjoyed strong adoption among younger patients, there is a significant shift toward older patients, including those aged 27-42 and 43-65. Meanwhile, Baird lowered its price target on the stock to $107 from $121 while reiterating an Outperform rating. The new price target represents significant upside potential given that the stock trades at about $41 a share. The research firm remains bullish on the company's stock, projecting sales of $90 to $92 million for its Vykat drug, exceeding its $82 million e
Show less
Read more
Impact Snapshot
Event Time:
SLNO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SLNO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SLNO alerts
High impacting Soleno Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
SLNO
News
- Soleno Therapeutics (NASDAQ:SLNO) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.MarketBeat
- Down 18.3% in 4 Weeks, Here's Why Soleno Therapeutics (SLNO) Looks Ripe for a Turnaround [Yahoo! Finance]Yahoo! Finance
- Soleno Therapeutics to Participate in Upcoming Conferences [Yahoo! Finance]Yahoo! Finance
- Soleno Therapeutics to Participate in Upcoming ConferencesGlobeNewswire
- Soleno Therapeutics (NASDAQ:SLNO) had its "sell (d-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
SLNO
Earnings
- 11/4/25 - Beat
SLNO
Sec Filings
- 1/23/26 - Form 4
- 1/23/26 - Form 4
- 1/23/26 - Form 4
- SLNO's page on the SEC website